Different markers for minimal systemic disease detection in lung cancer patients.

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F11%3A33119771" target="_blank" >RIV/61989592:15110/11:33119771 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Different markers for minimal systemic disease detection in lung cancer patients.
Original language description
Objectives. The role of circulating tumor cells and nucleic acids in prognostication in non-small cell lung cancer patients is controversial, but may be better defined with advancing technologies of detection of such cells or free tumor DNA with higher precision, and improved clinical-pathological correlations. Biomarker measurements of minimal systemic disease (MSD) have the potential to monitor the molecular status of tumors without invasive tumor biopsy at the time of treatment selection. Patients: This is a pilot study to test for the presence of the minimal systemic disease in 69 lung cancer patients undergoing curative surgery. Methods: We used real-time RT-PCR method for absolute gene expression quantification of carcinoembryonic antigen (CEA),epidermal growth factor receptor 1 (EGFR1), palate, lung and nasal epithelium associated protein (LUNX) and hepatocyte growth factor receptor (c-met) in peripheral blood, blood from pulmonary veins and samples of bone marrow. Conclusions:
Czech name
—
Czech description
—

Project
<a href="/en/project/NS10285" target="_blank" >NS10285: Clinical significance of minimal residual disease in patients with operable lung cancer</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)